JAIME GIRON: Open Payments
NPI 1346321197 · SOLEDAD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$894 in 37 payments from 8 companies in 2025. Trend: 2023 $2,161 · 2024 $1,333 · 2025 $894
Food & beverage: $894
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 12 | $304 |
| Novo Nordisk Inc | 12 | $260 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $116 |
| PFIZER INC. | 4 | $65 |
| Dexcom, Inc. | 3 | $60 |
| ABBVIE INC. | 2 | $40 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $33 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $17 |
Products named: JARDIANCE, Rybelsus, Ozempic, PREVNAR 20, Dexcom G6 Transmitter, QULIPTA, XIFAXAN, Wegovy.
Industry payments across CA — which companies pay providers there.
